17 results on '"He, Zhanghai"'
Search Results
2. Clinicopathological characteristics of IgG4-related lung disease
- Author
-
Liu, Jia, Liu, Yuxiang, Shen, Ximing, He, Zhanghai, Yu, Tingfeng, Pang, Li, Jin, Xiaoyan, and Wang, Lingyun
- Published
- 2021
- Full Text
- View/download PDF
3. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial
- Author
-
Wu, Wei, Chen, Jiewen, Deng, Heran, Jin, Liang, He, Zhanghai, Rao, Nanyan, Nie, Yan, Yao, Yandan, Yang, Yaping, Su, Fengxi, and Liu, Jieqiong
- Published
- 2021
- Full Text
- View/download PDF
4. Corrigendum to “CCL18-induced HOTAIR upregulation promotes malignant progression in esophageal squamous cell carcinoma through the miR-130a-5p-ZEB1 axis” [Cancer Lett. 460 (2019) 18–28]
- Author
-
Wang, Wenjian, Wu, Duoguang, He, Xiaotian, Hu, Xueting, Hu, Chuwen, Shen, Zhiwen, Lin, Jiatong, Pan, Zihao, He, Zhanghai, Lin, Huayue, and Wang, Minghui
- Published
- 2024
- Full Text
- View/download PDF
5. LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9
- Author
-
Fu, Zhiqiang, Chen, Changhao, Zhou, Quanbo, Wang, Yinxue, Zhao, Yue, Zhao, Xiaohui, Li, Wenzhu, Zheng, Shangyou, Ye, Huilin, Wang, Lin, He, Zhanghai, Lin, Qing, Li, Zhihua, and Chen, Rufu
- Published
- 2017
- Full Text
- View/download PDF
6. circGSK3β promotes metastasis in esophageal squamous cell carcinoma by augmenting β-catenin signaling
- Author
-
Hu, Xueting, Wu, Duoguang, He, Xiaotian, Zhao, Huiying, He, Zhanghai, Lin, Jiatong, Wang, Kefeng, Wang, Wenjian, Pan, Zihao, Lin, Huayue, and Wang, Minghui
- Published
- 2019
- Full Text
- View/download PDF
7. Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer
- Author
-
Yang, Yaping, Wang, Ying, Deng, Heran, Tan, Cui, Li, Qian, He, Zhanghai, Wei, Wei, Zhou, Enxiang, Liu, Qiang, and Liu, Jieqiong
- Published
- 2019
- Full Text
- View/download PDF
8. Effect of 1H‐NMR serum lipoproteins on immunotherapy response in advanced triple‐negative breast cancer patients.
- Author
-
Tian, Zhenluan, Rao, Qunxian, He, Zhanghai, Zhao, Wei, Chen, Liangyu, Liu, Jieqiong, and Wang, Ying
- Abstract
We previously reported the results of a phase II trial of anti‐PD‐1 antibody plus anti‐vascular endothelial growth factor receptor 2 inhibitors and eribulin in heavily pretreated advanced triple‐negative breast cancer with a favorable objective response rate (ORR) of 37.0% (NCT04303741). Here we report updated survival outcomes and serum metabolite changes of the study. Proton nuclear magnetic resonance spectroscopy was used to detect metabolite dynamics and explore biomarkers for response. We found that treatment‐sensitive patients had higher very low‐density lipoprotein‐related metabolite expression at baseline. A lipid proteomics model consisting of six metabolites predicted ORR and progression‐free survival at 6 months with area under the receiver operating characteristic curves of 0.88 and 0.87, respectively. Serum asparagine and sarcosine concentrations were significantly higher after treatment in treatment‐resistant patients. In conclusion, we constructed a model consisting of six metabolites to identify patients who benefit more from the triplet treatment, and asparagine and sarcosine may be associated with treatment resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Genomic Signature of Driver Genes Identified by Target Next‐Generation Sequencing in Chinese Non‐Small Cell Lung Cancer.
- Author
-
Wen, Shiwang, Dai, Lei, Wang, Lei, Wang, Wenjian, Wu, Duoguang, Wang, Kefeng, He, Zhanghai, Wang, Aodi, Chen, Hui, Zhang, Peng, Dong, Xiaowei, Dong, Yu‐An, Wang, Kai, Yao, Ming, and Wang, Minghui
- Subjects
LUNG cancer & genetics ,ADENOCARCINOMA ,DISEASE susceptibility ,EPIDERMAL growth factor ,GENE expression ,GENES ,GENOMES ,GENETIC mutation ,DESCRIPTIVE statistics ,SEQUENCE analysis ,GENOTYPES - Abstract
Background: Non‐small cell lung cancer (NSCLC) is one of the most common human malignancies and the leading cause of cancer‐related death. Over the past few decades, genomic alterations of cancer driver genes have been identified in NSCLC, and molecular testing and targeted therapies have become standard care for lung cancer patients. Here we studied the unique genomic profile of driver genes in Chinese patients with NSCLC by next‐generation sequencing (NGS) assay. Materials and Methods: A total of 1,200 Chinese patients with NSCLC were enrolled in this study. The median age was 60 years (range: 26–89), and 83% cases were adenocarcinoma. NGS‐based genomic profiling of major lung cancer‐related genes was performed on formalin‐fixed paraffin‐embedded tumor samples and matched blood. Results: Approximately 73.9% of patients with NSCLC harbored at least one actionable alteration recommended by the National Comprehensive Cancer Network guideline, including epidermal growth factor receptor (EGFR), ALK, ERBB2, MET, BRAF, RET, and ROS1. Twenty‐seven patients (2.2%) harbored inherited germline mutations of cancer susceptibility genes. The frequencies of EGFR genomic alterations (both mutations and amplification) and ALK rearrangement were identified as 50.1% and 7.8% in Chinese NSCLC populations, respectively, and significantly higher than the Western population. Fifty‐six distinct uncommon EGFR mutations other than L858R, exon19del, exon20ins, or T790M were identified in 18.9% of patients with EGFR‐mutant NSCLC. About 7.4% of patients harbored both sensitizing and uncommon mutations, and 11.6% of patients harbored only uncommon EGFR mutations. The uncommon EGFR mutations more frequently combined with the genomic alterations of ALK, CDKN2A, NTRK3, TSC2, and KRAS. In patients <40 years of age, the ALK‐positive percentage was up to 28.2%. Moreover, 3.2% of ALK‐positive patients harbored multi ALK rearrangements, and seven new partner genes were identified. Conclusion: More unique features of cancer driver genes in Chinese NSCLC were identified by next‐generation sequencing. These findings highlighted that NGS technology is more feasible and necessary than other molecular testing methods, and suggested that the special strategies are needed for drug development and targeted therapy for Chinese patients with NSCLC. Implications for Practice: Molecular targeted therapy is now the standard first‐line treatment for patients with advanced non‐small cell lung cancer (NSCLC). Samples of 1,200 Chinese patients with NSCLC were analyzed through next‐generation sequencing to characterize the unique feature of uncommon EGFR mutations and ALK fusion. The results showed that 7.4% of EGFR‐mutant patients harbored both sensitizing and uncommon mutations and 11.6% harbored only uncommon mutations. Uncommon EGFR mutations more frequently combined with the genomic alterations of ALK, CDKN2A, NTRK3, TSC2, and KRAS. ALK fusion was more common in younger patients, and the frequency decreased monotonically with age. 3.2% of ALK‐positive patients harbored multi ALK rearrangement, and seven new partner genes were identified. Lung cancer is the most fatal malignancy in China. This study assessed genomic alterations of driver genes in a cohort of Chinese patients with non‐small cell lung cancer. This article reports the resulting analysis of germline mutations, EGFR variations, and ALK rearrangements, the most common and important driver genes in Chinese NSCLC population. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. CCL18-induced HOTAIR upregulation promotes malignant progression in esophageal squamous cell carcinoma through the miR-130a-5p-ZEB1 axis.
- Author
-
Wang, Wenjian, Wu, Duoguang, He, Xiaotian, Hu, Xueting, Hu, Chuwen, Shen, Zhiwen, Lin, Jiatong, Pan, Zihao, He, Zhanghai, Lin, Huayue, and Wang, Minghui
- Subjects
- *
SQUAMOUS cell carcinoma , *NON-coding RNA , *CANCER invasiveness , *ESOPHAGEAL cancer , *METASTASIS - Abstract
Accumulating evidence indicates that CCL18 and the long non-coding RNA, HOTAIR, have critical roles in cancer progression and metastasis, but the correlation between CCL18 and HOTAIR in esophageal squamous cell carcinoma (ESCC) and their downstream molecular mechanisms remain unclear. Overexpression of CCL18 in ESCC tissues was associated with a worse survival in patients with ESCC. CCL18 enhanced the invasiveness of ESCC cells in a dose-dependent manner, whereas CCL18 knockdown inhibited their invasiveness. In particular, CCL18 expression was positively associated with HOTAIR expression in ESCC tissues. Furthermore, CCL18 upregulated the expression of HOTAIR, and knockdown of HOTAIR alleviated the CCL18-induced invasiveness of ESCC cells. HOTAIR may act as a competing endogenous RNA and could effectively becoming a sponge for miR-130a-5p, thereby modulating the derepression of ZEB1 and promoting epithelial-mesenchymal transition in ESCC. Our study suggests that CCL18 contributes to the malignant progression of esophageal cancer by upregulating HOTAIR expression. HOTAIR overexpression may promote tumor invasiveness and progression in ESCC, given that HOTAIR functions as a miR-130a-5p sponge, positively regulating ZEB1. This provides new therapeutic targets for early diagnosis and treatment of ESCC. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
11. Corrigendum to "LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9" [Canc. Lett. 410 (2017) 68-81].
- Author
-
Fu, Zhiqiang, Chen, Changhao, Zhou, Quanbo, Wang, Yinxue, Zhao, Yue, Zhao, Xiaohui, Li, Wenzhu, Zheng, Shangyou, Ye, Huilin, Wang, Lin, He, Zhanghai, Lin, Qing, Li, Zhihua, and Chen, Rufu
- Published
- 2022
- Full Text
- View/download PDF
12. lncRNA-WAL promotes triple-negative breast cancer aggression by inducing β-catenin nuclear translocation.
- Author
-
Huang H, Jin H, Lei R, He Z, He S, Chen J, Saw PE, Qiu Z, Ren G, and Nie Y
- Abstract
Because of its insensitivity to existing radiotherapy, namely chemotherapy and targeted treatments, triple-negative breast cancer (TNBC) remains a great challenge to overcome. Increasing evidence has indicated abnormal Wnt/β-catenin pathway activation in TNBC but not luminal or HER2+ breast cancer, and lncRNAs play a key role in a variety of cancers. Through lncRNA microarray profiling between activated and inactivated wnt/β-catenin pathway of TNBC tissues, lnc-WAL (wnt/β-catenin associated lncRNA; WAL) was selected as the top upregulated lncRNA in wnt/β-catenin pathway activation compared with the inactivation group. RIP-seq was used to compare the β-catenin and IgG groups, where lnc-WAL could interact with β-catenin. Clinically, increased lnc-WAL in TNBC tumor tissue was associated with shorter survival. lnc-WAL promoted EMT, the proliferation, migration and invasion of breast cancer stem cells (BCSCs), and TNBC cells. Mechanistically, lnc-WAL inhibited β-catenin protein degradation via Axin-mediated phosphorylation at serine 45. Subsequently, β-catenin accumulated in the nucleus and activated the target genes. Importantly, wnt/β-catenin pathway activation stimulated the transcription of lnc-WAL. These results pointed to a master regulatory role of lnc-WAL/Axin/β-catenin in the malignant progression of TNBC. Our findings provide important clinical translational evidence that lnc-WAL may be a potential therapeutic target against TNBC. Implications: The positive feedback between lnc-WAL and the Wnt/β-catenin pathway promotes TNBC progression, and lnc-WAL could be a potential prognostic marker for TNBC patients.
- Published
- 2024
- Full Text
- View/download PDF
13. Effect of 1 H-NMR serum lipoproteins on immunotherapy response in advanced triple-negative breast cancer patients.
- Author
-
Tian Z, Rao Q, He Z, Zhao W, Chen L, Liu J, and Wang Y
- Abstract
We previously reported the results of a phase II trial of anti-PD-1 antibody plus anti-vascular endothelial growth factor receptor 2 inhibitors and eribulin in heavily pretreated advanced triple-negative breast cancer with a favorable objective response rate (ORR) of 37.0% (NCT04303741). Here we report updated survival outcomes and serum metabolite changes of the study. Proton nuclear magnetic resonance spectroscopy was used to detect metabolite dynamics and explore biomarkers for response. We found that treatment-sensitive patients had higher very low-density lipoprotein-related metabolite expression at baseline. A lipid proteomics model consisting of six metabolites predicted ORR and progression-free survival at 6 months with area under the receiver operating characteristic curves of 0.88 and 0.87, respectively. Serum asparagine and sarcosine concentrations were significantly higher after treatment in treatment-resistant patients. In conclusion, we constructed a model consisting of six metabolites to identify patients who benefit more from the triplet treatment, and asparagine and sarcosine may be associated with treatment resistance., (© 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
- Published
- 2023
- Full Text
- View/download PDF
14. PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK.
- Author
-
Zhou Q, Zhou Q, Liu Q, He Z, Yan Y, Lin J, Chen Z, He C, Mao K, Wang J, Zhou Z, Xiao Z, and Zhang J
- Subjects
- Animals, Carcinoma, Hepatocellular pathology, Cell Line, Tumor, Cell Movement genetics, Cell Proliferation genetics, DNA Copy Number Variations genetics, Disease Progression, Female, Gene Expression Regulation, Neoplastic genetics, Humans, Liver Neoplasms pathology, Mice, Mice, Inbred BALB C, Mice, Nude, Oncogenes genetics, Phosphatidylinositol 3-Kinases genetics, Phosphorylation genetics, Prognosis, Signal Transduction genetics, Up-Regulation genetics, Carcinoma, Hepatocellular genetics, Focal Adhesion Kinase 1 genetics, Liver Neoplasms genetics, Neoplasm Proteins genetics, Protein Tyrosine Phosphatases genetics
- Abstract
Background: In addition to protein tyrosine kinases, accumulating evidence has shown that protein tyrosine phosphatases (PTPs) are suitable therapeutic targets in cancer. PRL-3 is a PTP member that has been well studied in many malignant tumours. The goal of the present study was to elucidate the role of PRL-3 in hepatocellular carcinoma (HCC), which remains largely unknown. Methods: Bioinformatic and immunohistochemical analyses were performed to analyse PRL-3 expression in HCC tissue samples and determine its clinical relevance. PRL-3 gene copy number variations were evaluated by bioinformatic analysis and quantitative-genomic polymerase chain reaction. The biological functions of PRL-3 were investigated in vivo and vitro. Gene microarray assays, RT-qPCR, western blotting and luciferase experiments were performed to identify the downstream effectors of PRL-3 that mediate its functions in HCC. Results: PRL-3 expression was upregulated in HCC samples from public databases and in cohort samples from our centre. High PRL-3 expression was associated with poor prognosis. Copy number gains and amplification of chromosome 8q24.3 in HCC were determined to be positively correlated with the PRL-3 overexpression. PRL-3 overexpression promoted HCC cell proliferation, migration and adhesion, while its loss had the opposite effects. Further study showed that focal adhesion kinase (FAK) was co-amplified and co-expressed with PRL-3 in HCC. Interestingly, PRL-3 also promoted the phosphorylation of FAK, which subsequently mediated the oncogenic functions of PRL-3 in HCC cells. Moreover, TGFB1 was identified as a downstream molecule of PRL-3. TGF-β signalling was shown to mediate the PRL-3-induced activation of FAK. Furthermore, the p38 and PI3K/AKT pathways were observed to mediate the PRL-3-induced expression of TGFB1 and the subsequent activation of FAK, while the activation of FAK in turn stimulated activation of the p38 and PI3K/AKT pathways, forming a PRL-3-triggered AKT/p38/TGFB1/FAK positive feedback loop. Conclusion: Collectively, our findings indicate that the PTP PRL-3 plays a crucial role in the progression of HCC and provides an example of how co-amplified genes work together in HCC., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)
- Published
- 2020
- Full Text
- View/download PDF
15. Overexpression of gasdermin D promotes invasion of adenoid cystic carcinoma.
- Author
-
Shen X, Zhang Q, He Z, Xiao S, Li H, and Huang Z
- Abstract
Objective: To investigate the relationship between gasdermin D (GSDMD) expression and the invasion of adenoid cystic carcinoma (ACC)., Methods: Immunohistochemistry (IHC) was used to examine GSDMD expression in tumours and adjacent non-cancerous (ANC) tissues from 33 patients with salivary ACC patients and in tumour samples from 29 patients with pleomorphic adenoma (PA). Lentiviral infection was used to stably overexpress GSDMD in ACC-LM and ACC-83 cells (GSDMD-ov cells), which were subjected to transwell and scratch tests to assess their invasive abilities compared to control cells. Cells overexpressing GSDMD were treated with siRNA targeting GSDMD, and their invasive ability was subsequently examined., Results: GSDMD expression was significantly higher in ACC tissues than in corresponding ANC tissues (P<0.001). After 24 hours, both the ACC-83 and ACC-LM GSDMD-ov cell lines had more cells that moved through the membrane than did the control cells (P<0.05). For the wound healing experiment, the diameter of the wound in the GSDMD-ov cell lines was smaller than that of the control cells (P<0.001) after 24 hours. The ACC cell lines expressing high GSDMD showed stronger metastatic ability than did the control., Conclusion: GSDMD was highly expressed in ACC tissues compared to ANC tissues, and high GSDMD expression promoted the invasion of ACC cells. These findings suggest that GSDMD expression is related to the invasion of ACC. Our data indicate that we may be able to use GSDMD as an indicator of the invasive or metastatic potential of tumour cells in future research., Competing Interests: None., (IJCEP Copyright © 2020.)
- Published
- 2020
16. Re-excision or "wait and watch"-a prediction model in breast phyllodes tumors after surgery.
- Author
-
Chao X, Jin X, Tan C, Sun P, Cui J, Hu H, Ouyang Q, Chen K, Wu W, He Z, Nie Y, and Yao H
- Abstract
Background: The prognosis of breast phyllodes tumors (PTs) largely depending on the pathological grading, which lacks objectivity. This study aimed to develop a nomogram based on clinicopathological features to evaluate the recurrence probability of PTs following surgery., Methods: Data from 334 patients with breast PTs, who underwent surgical treatment at Sun Yat-sen Memorial Hospital from January 2005 to December 2014, were used to develop a prediction model. Additionally, data of 36 patients from Peking University Shenzhen Hospital (cohort 1) and data of 140 patients from Sun Yat-sen University Cancer Center (cohort 2) during the same period were used to validate the model. The medical records and tumor slides were retrospectively reviewed. The log-rank and Cox regression tests were used to develop a clinical prediction model of breast PTs. All statistical analyses were performed using R and STATA., Results: Of all 334 patients included in the primary cohort, 224 had benign, 91 had borderline, and 19 had malignant tumors. The 1-, 3-, and 5-year recurrence-free survival was 98.5%, 97.9%, and 96.8%, respectively. Ultrasound-guided vacuum-assisted biopsy (UGVAB) is a non-inferior treatment application in benign PTs compared with open surgery [hazard ratio (HR), 2.38; 95% confidence interval (CI), 0.59-9.58]. Width of surgical margin, mitoses, and tumor border were identified as independent risk factors for breast PTs. A nomogram was developed based on these three variables. The C-index of internal and external validation was 0.71, 0.67 (cohort 1) and 0.73 (cohort 2), respectively., Conclusions: The study model presented more concise and objective variables to evaluate the recurrence-free survival of patients after surgery, which can help deciding whether to do a re-excision or "wait and watch"., Competing Interests: Conflicts of Interest: The authors have no conflicts of interest to declare., (2020 Annals of Translational Medicine. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
17. HIF-1α Promotes the Metastasis of Esophageal Squamous Cell Carcinoma by Targeting SP1.
- Author
-
Hu X, Lin J, Jiang M, He X, Wang K, Wang W, Hu C, Shen Z, He Z, Lin H, Wu D, and Wang M
- Abstract
Background: In microenvironment of malignant tumors, Hypoxia-Inducible Factors (HIF), most importantly HIF-1α, play an important role in regulation of adaptive biological response to hypoxia, promoting angiogenesis and metastasis. However, the underlying mechanism that HIF-1α regulates metastasis needs to be further clarified. Methods: The expressions of HIF-1α and SP1 were detected in 182 samples of esophageal squamous cell carcinoma (ESCC) and adjacent normal tissues by immunohistochemistry (IHC), and the correlation between the expression levels of HIF-1α and SP1 was analyzed. The expression of HIF-1α in ESCC cell lines TE1 and KYSE30 was then detected using qRT-PCR and western blot. The potential binding sites of HIF-1α on the SP1 promoter were analyzed using UCSC and JASPAR databases, verified by chromosomal immunoprecipitation (ChIP) assay and qRT-PCR. The effects of HIF-1α and SP1 on ESCC cell migration and invasion were then tested with Transwell and Matrigel experiments. Results: The expression of HIF-1α in cancer tissues is higher than adjacent normal tissues, and is correlated with metastasis, recurrence and poor prognosis. Upon silencing HIF-1α by siRNA, the invasion and migration ability of ESCC cells were significantly inhibited, which could be restored by the overexpression of SP1. Hypoxic conditions significantly increased the expression of HIF-1α and SP1 at both protein and mRNA levels in ESCC cells. HIF-1α enhanced SP1 transcription through binding to the promoter region. The expression of protein and mRNA levels of SP1 was decreased by silencing HIF-1α in cells. In contrast, overexpression of HIF-1α significantly increased the mRNA and protein levels of SP1. The expression of SP1 in ESCC was positively correlated with the protein expression of HIF-1α and poor prognosis. Conclusion: The results of our study indicate that HIF-1α promotes metastasis of ESCC by targeting SP1 in a hypoxic microenvironment. Further study on this mechanism may elucidate the possibility of HIF-1α and SP1 as new targets for the treatment of ESCC., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.